Navigation Links
CRF announces late breaking trials and first report investigations to be presented at TCT 2010
Date:8/5/2010

NEW YORK, NY August 5, 2010 The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. Findings from these clinical trials are expected to significantly impact interventional cardiology practices and patient care. TCT 2010 will take place September 21 25 in Washington, DC.

The studies selected will shed new light on the effectiveness of minimally invasive techniques, pharmaceuticals, technologies and devices that show potential to treat or prevent heart disease, one of the leading causes of death globally.

Late-breaking clinical trials and first report investigations will be highlighted during press conferences scheduled for Thursday, September 23, Friday, September 24, and Saturday, September 25.

THURSDAY, SEPTEMBER 23
Late Breaking Trials

  • PARTNER: A Prospective Randomized Trial of Transcatheter Aortic Valve Implantation Compared to Standard Therapy in Patients with Inoperable Aortic Stenosis
  • SPIRIT IV: Two-Year Results from a Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease
  • COMPARE: Two-Year Results from a Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease

First Report Investigations

  • LANCELOT ACS: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Reversible PAR-1 Thrombin Receptor Antagonist in Patients with Acute Coronary Syndromes
  • LEVANT I: A Prospective Randomized Trial of a Paclitaxel-Eluting Balloon Compared to a Non-Drug-Eluting Balloon With and Without Stenting in Patients with Diseased Femoropopliteal Arteries
  • PERfECT STENT: A Prospective Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients Treated with Endothelial Progenitor Cell Capturing Stents for De Novo Coronary Artery Disease

FRIDAY, SEPTEMBER 24
Late Breaking Trials

  • ZILVER PTX: A Prospective Randomized Trial of a Paclitaxel-Eluting Stent Compared to Balloon Angioplasty with Provisional Bare Metal Stenting in Patients with Superficial Femoral Artery Disease
  • SORT OUT 4: A Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
  • ISAR-TEST-4: Two-Year Clinical and Angiographic Outcomes from a Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease

First Report Investigations

  • DES-BTK: A Prospective, Double-Blind, Randomized Trial of Polymer-Free Sirolimus-Eluting Stents Compared to Bare Metal Stents in Patients with Infrapopliteal Disease
  • TORPEDO: A Prospective Randomized Trial of Percutaneous Endovenous Intervention Compared to Anticoagulation Alone in Patients with Deep Venous Thrombosis
  • BLAST: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Monocyte-Depleting Agent After Bare Metal Stents in Patients with Coronary Artery Disease

SATURDAY, SEPTEMBER 25
Late Breaking Trials

  • ISAR-TEST-5: A Prospective Randomized Trial of Polymer-Free Sirolimus-/Probucol-Eluting Stents Compared to Zotarolimus-Eluting Stents in Patients with Coronary Artery Disease
  • HORIZONS-AMI: Three-Year Follow-up from a Prospective Randomized Trial of Antithrombin Strategies and Drug-Eluting Stents in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty
  • CRISTAL: A Prospective Randomized Trial of Sirolimus-Eluting Stents Compared to Balloon Angioplasty for Restenosis of Drug-Eluting Coronary Stents

First Report Investigations

  • BIOFREEDOM: A Prospective Randomized Trial of Polymer-Free Biolimus A9-Eluting Stents and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease
  • AVIO: A Prospective Randomized Trial of Intravascular Ultrasound-Guided Compared to Angiography-Guided Stent Implantation in Complex Coronary Lesions
  • EXCELLENT: A Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. ASP announces 2010 T. Franklin Williams Scholars
2. Feng Shui Expert Practitioner and Analyst Angel de Para Announces Classical Feng Shui Practitioner Workshop in New York City.
3. Lifeloc supports workplace breath alcohol testing and announces new robust solution, the EV30T
4. QualEDIx Announces the Launch of the Nation's Only Managed Service Model for HIPAA 5010 and ICD-10 Testing
5. ASTRO announces 2010 Fellows class
6. NOSCAR announces first NOTES transoral and transvaginal gallbladder removals performed as part of US multicenter human trial
7. Bling My Sling LL Announces Website Launch - A fashionable arm sling manufacturer, announce the opening of their new website bling-my-sling.com
8. Health Literacy Innovations Announces 1st Annual Health Literacy Innovator Award — Anonymous Donor Offers Prize Money To Winners
9. IVR Technology Group Announces MobileMarketing123.com
10. RSLSteeper announces pricing for new bionic hand
11. SNMs Technologist Section announces award winners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Salucro, the cloud-based payment platform ... industry’s hospitals and provider groups, has announced that it will now offer Parasail’s ... is a San Francisco health-finance startup that has launched a series of tech-based ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... SUNucate efforts, Louisiana became the sixth state to pass legislation which ensures ... John Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, Utah ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th article ... reach a staggering $6.81 billion by the year 2024 according to a new report. ... rate than those made from titanium. Los Angeles area clinic Beverly Hills Periodontics & ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Kelahan Agency, a ... to residents of southern New Hampshire, is teaming up with the New Horizons ... and homelessness in the region. , New Horizons for New Hampshire provides a ...
(Date:6/27/2017)... Portland, Ore. (PRWEB) , ... June 27, 2017 ... ... Provider (CSP), today announced the expansion of Atmosera Managed Azure Services . ... now includes enhancements in support of the company’s growing customer base. Atmosera’s next ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 2017  StatLab Medical Products ("StatLab" or ... of diagnostic supplies for the anatomic pathology ... Company LP ("Cressey & Company"), a healthcare-focused ... investment in the Company. Cressey & Company ... selling shareholder, Prairie Capital, L.P., with certain ...
(Date:6/5/2017)... June 5, 2017 The Cincinnati ... Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded a ... . Results are based on an employee survey ... health and workplace improvement. The survey measures several aspects of ... ...
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
Breaking Medicine Technology: